ATE401097T1 - Verwendung von imidazochinolinaminen als adjuvantien in dna-impfung - Google Patents
Verwendung von imidazochinolinaminen als adjuvantien in dna-impfungInfo
- Publication number
- ATE401097T1 ATE401097T1 AT01967535T AT01967535T ATE401097T1 AT E401097 T1 ATE401097 T1 AT E401097T1 AT 01967535 T AT01967535 T AT 01967535T AT 01967535 T AT01967535 T AT 01967535T AT E401097 T1 ATE401097 T1 AT E401097T1
- Authority
- AT
- Austria
- Prior art keywords
- imidazocinolinamines
- adjuvants
- dna vaccination
- vaccination
- dna
- Prior art date
Links
- 238000011238 DNA vaccination Methods 0.000 title 1
- 239000002671 adjuvant Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0023008.6A GB0023008D0 (en) | 2000-09-20 | 2000-09-20 | Improvements in vaccination |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE401097T1 true ATE401097T1 (de) | 2008-08-15 |
Family
ID=9899764
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01967535T ATE401097T1 (de) | 2000-09-20 | 2001-09-20 | Verwendung von imidazochinolinaminen als adjuvantien in dna-impfung |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US20040076633A1 (de) |
| EP (1) | EP1318835B1 (de) |
| JP (1) | JP2004509150A (de) |
| KR (1) | KR100876263B1 (de) |
| CN (1) | CN1197620C (de) |
| AR (1) | AR035586A1 (de) |
| AT (1) | ATE401097T1 (de) |
| AU (2) | AU2001287908B2 (de) |
| BR (1) | BR0113982A (de) |
| CA (1) | CA2422863A1 (de) |
| CZ (1) | CZ2003792A3 (de) |
| DE (1) | DE60134866D1 (de) |
| ES (1) | ES2309086T3 (de) |
| GB (1) | GB0023008D0 (de) |
| HU (1) | HUP0301180A3 (de) |
| IL (1) | IL154947A0 (de) |
| MX (1) | MXPA03002453A (de) |
| MY (1) | MY138978A (de) |
| NO (1) | NO20031274L (de) |
| NZ (1) | NZ524792A (de) |
| PL (1) | PL360895A1 (de) |
| TW (1) | TWI287453B (de) |
| WO (1) | WO2002024225A1 (de) |
| ZA (1) | ZA200302231B (de) |
Families Citing this family (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| IL139813A0 (en) | 1998-05-22 | 2002-02-10 | Loeb Health Res Inst At The Ot | Methods and products for inducing mucosal immunity |
| US6677347B2 (en) * | 2000-12-08 | 2004-01-13 | 3M Innovative Properties Company | Sulfonamido ether substituted imidazoquinolines |
| WO2003080114A2 (en) * | 2002-03-19 | 2003-10-02 | Powdermed Limited | Imidazoquinoline adjuvants for vaccines |
| US20050266024A1 (en) * | 2002-03-19 | 2005-12-01 | Powdermed Limited | Adjuvant |
| GB0206461D0 (en) * | 2002-03-19 | 2002-05-01 | Glaxo Group Ltd | Improvements in vaccination |
| ATE488246T1 (de) * | 2002-08-15 | 2010-12-15 | 3M Innovative Properties Co | Immunstimulatorische zusammensetzungen und verfahren zur stimulierung einer immunantwort |
| CA2510375A1 (en) | 2002-12-20 | 2004-07-15 | 3M Innovative Properties Company | Aryl / hetaryl substituted imidazoquinolines |
| US7731967B2 (en) * | 2003-04-30 | 2010-06-08 | Novartis Vaccines And Diagnostics, Inc. | Compositions for inducing immune responses |
| AR045261A1 (es) * | 2003-08-12 | 2005-10-19 | 3M Innovative Properties Co | Compuestos que contienen imidazo quinolina o imidazo piridina sustituidos; composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos inmunomoduladores |
| JP2007503268A (ja) * | 2003-08-25 | 2007-02-22 | スリーエム イノベイティブ プロパティズ カンパニー | 免疫応答修飾化合物の送達 |
| EP1660122A4 (de) * | 2003-08-25 | 2007-10-24 | 3M Innovative Properties Co | Immunstimulatorische kombinationen und behandlungen |
| ES2406730T3 (es) | 2003-08-27 | 2013-06-07 | 3M Innovative Properties Company | Imidazoquinolinas sustituidas con ariloxi y arilalquilenoxi |
| AU2004270201A1 (en) * | 2003-09-05 | 2005-03-17 | 3M Innovative Properties Company | Treatment for CD5+ B cell lymphoma |
| US20090075980A1 (en) * | 2003-10-03 | 2009-03-19 | Coley Pharmaceutical Group, Inc. | Pyrazolopyridines and Analogs Thereof |
| US7544697B2 (en) | 2003-10-03 | 2009-06-09 | Coley Pharmaceutical Group, Inc. | Pyrazolopyridines and analogs thereof |
| AR046046A1 (es) * | 2003-10-03 | 2005-11-23 | 3M Innovative Properties Co | Imidazoquinolinas alcoxi sustituidas. composiciones farmaceuticas. |
| US7897767B2 (en) | 2003-11-14 | 2011-03-01 | 3M Innovative Properties Company | Oxime substituted imidazoquinolines |
| CA2545825A1 (en) * | 2003-11-14 | 2005-06-02 | 3M Innovative Properties Company | Hydroxylamine substituted imidazo ring compounds |
| MXPA06005910A (es) | 2003-11-25 | 2006-08-23 | 3M Innovative Properties Co | Sistemas de anillo imidazo sustituido y metodos. |
| EP1701955A1 (de) * | 2003-12-29 | 2006-09-20 | 3M Innovative Properties Company | Arylalkenyl- und arylalkinylsubstituierte imidazochinoline |
| WO2005066169A2 (en) * | 2003-12-30 | 2005-07-21 | 3M Innovative Properties Company | Imidazoquinolinyl, imidazopyridinyl, and imidazonaphthyridinyl sulfonamides |
| CA2559863A1 (en) * | 2004-03-24 | 2005-10-13 | 3M Innovative Properties Company | Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines |
| WO2005123080A2 (en) * | 2004-06-15 | 2005-12-29 | 3M Innovative Properties Company | Nitrogen-containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines |
| US8026366B2 (en) * | 2004-06-18 | 2011-09-27 | 3M Innovative Properties Company | Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines |
| WO2006009832A1 (en) * | 2004-06-18 | 2006-01-26 | 3M Innovative Properties Company | Substituted imidazo ring systems and methods |
| US7897609B2 (en) * | 2004-06-18 | 2011-03-01 | 3M Innovative Properties Company | Aryl substituted imidazonaphthyridines |
| WO2006065280A2 (en) * | 2004-06-18 | 2006-06-22 | 3M Innovative Properties Company | Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and methods |
| WO2006026760A2 (en) * | 2004-09-02 | 2006-03-09 | 3M Innovative Properties Company | 1-amino imidazo-containing compounds and methods |
| WO2006042254A2 (en) * | 2004-10-08 | 2006-04-20 | 3M Innovative Properties Company | Adjuvant for dna vaccines |
| DE102004049223A1 (de) * | 2004-10-08 | 2006-04-20 | Johannes-Gutenberg-Universität Mainz | Zubereitung zum Impfen, Impfverfahren und Verwendung einer Impf-Zubereitung |
| EP1819364A4 (de) * | 2004-12-08 | 2010-12-29 | 3M Innovative Properties Co | Immunmodulatorische zusammensetzungen, kombinationen und verfahren |
| PT1830876E (pt) * | 2004-12-30 | 2015-07-13 | Meda Ab | Utilização de imiquimod para o tratamento de metástases cutâneas derivadas de um tumor cancerígeno da mama |
| ES2392648T3 (es) | 2004-12-30 | 2012-12-12 | 3M Innovative Properties Company | Compuestos quirales sustituidos que contienen un núcleo 1,2-imidazo-4,5-c condensado |
| JP5543068B2 (ja) * | 2004-12-30 | 2014-07-09 | スリーエム イノベイティブ プロパティズ カンパニー | キラル縮合［１，２］イミダゾ［４，５−ｃ］環状化合物 |
| CA2597092A1 (en) | 2005-02-04 | 2006-08-10 | Coley Pharmaceutical Group, Inc. | Aqueous gel formulations containing immune reponse modifiers |
| CA2597587A1 (en) | 2005-02-11 | 2006-08-17 | Coley Pharmaceutical Group, Inc. | Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods |
| US7943610B2 (en) | 2005-04-01 | 2011-05-17 | 3M Innovative Properties Company | Pyrazolopyridine-1,4-diamines and analogs thereof |
| JP2008538550A (ja) | 2005-04-01 | 2008-10-30 | コーリー ファーマシューティカル グループ，インコーポレイテッド | ウイルス感染および腫瘍性疾患を処置するためのサイトカイン生合成の調節因子としての１−置換ピラゾロ（３，４−ｃ）環状化合物 |
| CA2620182A1 (en) | 2005-08-22 | 2007-03-01 | Dennis A. Carson | Tlr agonists |
| CA2621831A1 (en) * | 2005-09-09 | 2007-03-15 | Coley Pharmaceutical Group, Inc. | Amide and carbamate derivatives of n-{2-[4-amino-2- (ethoxymethyl)-1h-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethyl}methanesulfonamide and methods |
| ZA200803029B (en) * | 2005-09-09 | 2009-02-25 | Coley Pharm Group Inc | Amide and carbamate derivatives of alkyl substituted /V-[4-(4-amino-1H-imidazo[4,5-c] quinolin-1-yl)butyl] methane-sulfonamides and methods |
| JP5247458B2 (ja) * | 2005-11-04 | 2013-07-24 | スリーエム・イノベイティブ・プロパティーズ・カンパニー | ヒドロキシ及びアルコキシ置換１ｈ−イミダゾキノリン及び方法 |
| EP1988896A4 (de) | 2006-02-22 | 2011-07-27 | 3M Innovative Properties Co | Konjugate zur modifizierung von immunreaktionen |
| US8329721B2 (en) * | 2006-03-15 | 2012-12-11 | 3M Innovative Properties Company | Hydroxy and alkoxy substituted 1H-imidazonaphthyridines and methods |
| US8088788B2 (en) | 2006-03-15 | 2012-01-03 | 3M Innovative Properties Company | Substituted fused[1,2] imidazo[4,5-c] ring compounds and methods |
| CN101426514A (zh) * | 2006-04-25 | 2009-05-06 | 英特塞尔股份公司 | Hcv疫苗 |
| US20090060928A1 (en) * | 2006-05-26 | 2009-03-05 | Jean-Claude Bystryn | Topical Toll Like Receptor Ligands as Vaccine Adjuvants |
| WO2007142755A2 (en) | 2006-05-31 | 2007-12-13 | The Regents Of The University Of California | Purine analogs |
| EP2029169A2 (de) * | 2006-06-20 | 2009-03-04 | Transgene S.A. | Rekombinanter viraler impfstoff |
| JP5564249B2 (ja) | 2006-06-23 | 2014-07-30 | アレシア・バイオセラピューティクス・インコーポレーテッド | 癌に関与するポリヌクレオチド配列およびポリペプチド配列 |
| WO2008008432A2 (en) * | 2006-07-12 | 2008-01-17 | Coley Pharmaceutical Group, Inc. | Substituted chiral fused( 1,2) imidazo (4,5-c) ring compounds and methods |
| CN100450484C (zh) * | 2006-10-11 | 2009-01-14 | 北京科信必成医药科技发展有限公司 | 一种咪喹莫特混悬溶液及其凝胶剂 |
| ES2552471T3 (es) | 2007-02-07 | 2015-11-30 | The Regents Of The University Of California | Conjugados de agonistas de TLR sintéticos y usos de los mismos |
| CN101657213B (zh) * | 2007-02-15 | 2014-02-26 | 曼康公司 | 用于增强t细胞应答的方法 |
| US8709445B2 (en) | 2007-07-31 | 2014-04-29 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Vaccination with killed but metabolically active (KBMA) protozoans with toll-like receptor agonists |
| EP2244695A1 (de) | 2007-12-07 | 2010-11-03 | Novartis AG | Zusammensetzungen zur induktion von immunantworten |
| WO2010060186A1 (en) | 2008-11-03 | 2010-06-03 | Alethia Biotherapeutics Inc. | Antibodies that specifically block the biological activity of a tumor antigen |
| WO2010088924A1 (en) | 2009-02-06 | 2010-08-12 | Telormedix Sa | Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration |
| EP2508190B1 (de) * | 2009-12-03 | 2021-06-02 | Aureo Co., Ltd. | Makrophagen-phagozytose-aktivierende zusammensetzung und/oder zusammensetzung zur förderung der zytokinproduktion in makrophagen |
| CN101850117B (zh) * | 2010-06-03 | 2012-05-30 | 国家兽用生物制品工程技术研究中心 | 一种复方免疫佐剂及疫苗 |
| CA2808624C (en) | 2010-08-17 | 2019-05-14 | 3M Innovative Properties Company | Lipidated immune response modifier compound compositions, formulations, and methods |
| JP6294221B2 (ja) | 2011-03-31 | 2018-03-14 | アー・デー・ツェー・セラピューティクス・エス・アー | 腎臓関連抗原１に対する抗体およびその抗原結合性フラグメント |
| EP3366311B1 (de) | 2011-06-03 | 2020-02-26 | 3M Innovative Properties Co. | Hydrazino-1h-imidazochinolin-4-amine und daraus hergestellte konjugate |
| CA2838158C (en) | 2011-06-03 | 2019-07-16 | 3M Innovative Properties Company | Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom |
| TR201908872T4 (tr) | 2012-01-09 | 2019-07-22 | Adc Therapeutics Sa | Üçlü negatif meme kanserini tedavi etmek için ajanlar. |
| GB201310578D0 (en) | 2013-06-13 | 2013-07-31 | Univ Nottingham Trent | Electroactive actuators |
| CN105491982B (zh) | 2013-08-12 | 2019-09-10 | 3M创新有限公司 | 用于增强透皮递送的肽 |
| JP7145757B2 (ja) | 2015-10-12 | 2022-10-03 | リフロー メディカル インコーポレイテッド | 突出する薬剤送達フィーチャーを有するステント、ならびに、関連のシステムおよび方法 |
| US10533007B2 (en) | 2016-04-19 | 2020-01-14 | Innate Tumor Immunity, Inc. | NLRP3 modulators |
| EP3445761A1 (de) | 2016-04-19 | 2019-02-27 | Innate Tumor Immunity, Inc. | Nlrp3-modulatoren |
| US11697851B2 (en) | 2016-05-24 | 2023-07-11 | The Regents Of The University Of California | Early ovarian cancer detection diagnostic test based on mRNA isoforms |
| TWI674261B (zh) | 2017-02-17 | 2019-10-11 | 美商英能腫瘤免疫股份有限公司 | Nlrp3 調節劑 |
| WO2018217897A1 (en) * | 2017-05-23 | 2018-11-29 | David Weiner | Compositions and method for inducing an immune response |
| AU2018331874B2 (en) | 2017-09-13 | 2022-06-02 | Sanofi Pasteur | Human cytomegalovirus immunogenic composition |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL73534A (en) * | 1983-11-18 | 1990-12-23 | Riker Laboratories Inc | 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds |
| IL105325A (en) * | 1992-04-16 | 1996-11-14 | Minnesota Mining & Mfg | Immunogen/vaccine adjuvant composition |
| CA2269754A1 (en) * | 1996-10-23 | 1998-04-30 | American Home Products Corporation | Dna vaccines for herpes simplex virus 1 and 2 |
| GB9818627D0 (en) * | 1998-08-26 | 1998-10-21 | Glaxo Group Ltd | Improvements in dva vaccination |
-
2000
- 2000-09-20 GB GBGB0023008.6A patent/GB0023008D0/en not_active Ceased
-
2001
- 2001-09-20 DE DE60134866T patent/DE60134866D1/de not_active Expired - Lifetime
- 2001-09-20 NZ NZ524792A patent/NZ524792A/en not_active IP Right Cessation
- 2001-09-20 AU AU2001287908A patent/AU2001287908B2/en not_active Ceased
- 2001-09-20 AU AU8790801A patent/AU8790801A/xx active Pending
- 2001-09-20 MY MYPI20014415A patent/MY138978A/en unknown
- 2001-09-20 WO PCT/GB2001/004207 patent/WO2002024225A1/en not_active Ceased
- 2001-09-20 CN CNB018186173A patent/CN1197620C/zh not_active Expired - Fee Related
- 2001-09-20 IL IL15494701A patent/IL154947A0/xx unknown
- 2001-09-20 MX MXPA03002453A patent/MXPA03002453A/es active IP Right Grant
- 2001-09-20 AT AT01967535T patent/ATE401097T1/de not_active IP Right Cessation
- 2001-09-20 CA CA002422863A patent/CA2422863A1/en not_active Abandoned
- 2001-09-20 PL PL01360895A patent/PL360895A1/xx not_active Application Discontinuation
- 2001-09-20 US US10/380,981 patent/US20040076633A1/en not_active Abandoned
- 2001-09-20 ES ES01967535T patent/ES2309086T3/es not_active Expired - Lifetime
- 2001-09-20 BR BR0113982-7A patent/BR0113982A/pt not_active Application Discontinuation
- 2001-09-20 TW TW090123505A patent/TWI287453B/zh not_active IP Right Cessation
- 2001-09-20 CZ CZ2003792A patent/CZ2003792A3/cs unknown
- 2001-09-20 EP EP01967535A patent/EP1318835B1/de not_active Revoked
- 2001-09-20 KR KR1020037004041A patent/KR100876263B1/ko not_active Expired - Fee Related
- 2001-09-20 JP JP2002528295A patent/JP2004509150A/ja active Pending
- 2001-09-20 HU HU0301180A patent/HUP0301180A3/hu unknown
- 2001-09-20 AR ARP010104453A patent/AR035586A1/es unknown
-
2003
- 2003-03-19 NO NO20031274A patent/NO20031274L/no unknown
- 2003-03-20 ZA ZA200302231A patent/ZA200302231B/en unknown
-
2007
- 2007-06-19 US US11/764,814 patent/US20070248614A1/en not_active Abandoned
-
2010
- 2010-09-15 US US12/882,470 patent/US20110002953A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| GB0023008D0 (en) | 2000-11-01 |
| DE60134866D1 (de) | 2008-08-28 |
| JP2004509150A (ja) | 2004-03-25 |
| MXPA03002453A (es) | 2003-06-19 |
| NZ524792A (en) | 2004-09-24 |
| HUP0301180A3 (en) | 2005-11-28 |
| EP1318835B1 (de) | 2008-07-16 |
| BR0113982A (pt) | 2003-08-19 |
| ES2309086T3 (es) | 2008-12-16 |
| IL154947A0 (en) | 2003-10-31 |
| PL360895A1 (en) | 2004-09-20 |
| US20040076633A1 (en) | 2004-04-22 |
| CZ2003792A3 (cs) | 2004-12-15 |
| AR035586A1 (es) | 2004-06-16 |
| AU2001287908B2 (en) | 2005-06-30 |
| TWI287453B (en) | 2007-10-01 |
| NO20031274D0 (no) | 2003-03-19 |
| CN1197620C (zh) | 2005-04-20 |
| HK1057700A1 (en) | 2004-04-16 |
| KR100876263B1 (ko) | 2008-12-26 |
| ZA200302231B (en) | 2004-05-05 |
| MY138978A (en) | 2009-08-28 |
| WO2002024225A1 (en) | 2002-03-28 |
| US20070248614A1 (en) | 2007-10-25 |
| CA2422863A1 (en) | 2002-03-28 |
| CN1473051A (zh) | 2004-02-04 |
| NO20031274L (no) | 2003-05-19 |
| HUP0301180A2 (hu) | 2004-03-01 |
| KR20040023566A (ko) | 2004-03-18 |
| US20110002953A1 (en) | 2011-01-06 |
| EP1318835A1 (de) | 2003-06-18 |
| AU8790801A (en) | 2002-04-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE401097T1 (de) | Verwendung von imidazochinolinaminen als adjuvantien in dna-impfung | |
| DE69928763D1 (de) | Adjuvanzien zur Verwendung in Impfstoffen | |
| EP1294513A4 (de) | Lokalisationsspezifische kovalente biokonjugation von proteinen | |
| NO20031483L (no) | Vaksine | |
| CY2013025I2 (el) | Ετερολογος εκφραση των πρωτεϊνων της neisseria | |
| NO20024172D0 (no) | Vaksine | |
| DE50207852D1 (de) | Verwendung von fettalkoholethoxylaten als penetrationsförderer | |
| EP1418940A4 (de) | Dna expressionsvektoren und verwendungsverfahren | |
| DE60102489D1 (de) | Eintauchbarer in situ Oxygenator | |
| DE60126814D1 (de) | Inhalation von stickoxid | |
| DE60136400D1 (de) | Reinigung von hbv-Antigenen zur Verwendung in Impfstoffen | |
| DE50107834D1 (de) | Dispergierung von pigmenten in polyolefinen | |
| DE60129572D1 (de) | Verwendung von antikörpern gegen spezifische mhc-peptidkomplexe | |
| ATA192799A (de) | Neue verwendung von antikörpern als impfstoffe | |
| DE60112148T2 (de) | Verwendung von (Per)fluoroetherverbindungen als Zusatzstoffe in Formulierungen zur Holzbehandlung | |
| EP1446130A4 (de) | Ehrlichia-canis-gene und -impfstoffe | |
| DK1328289T3 (da) | Oxiderede proteiner og deres biologiske og terapuetiske aktivitet samt diagnostisk anvendelse ved hæmning af interaktion mellem oxiderede proteiner og CD36 | |
| DE60007360D1 (de) | Amorphe modifikation von torasemid | |
| EP1366056A4 (de) | Zubereitung von deoxynukleoside | |
| DE50010237D1 (de) | Verwendung von pit-emulsionen in fermentationsverfahren | |
| EP1490396A4 (de) | Immunogene hiv-peptide zur verwendung als reagentien und impfstoffe | |
| NO20030821D0 (no) | Gener og proteiner, og deres anvendelse | |
| ATA2152001A (de) | Verwendung von selenhältigen präparaten | |
| DE10195473D2 (de) | Verwendung von kompatiblen Soluten als Adjuvantien für Impfstoffe | |
| ITMI20012482A0 (it) | Diraspatore separatore-selezionatore di uva |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |